Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07221253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
December 4, 2025
Completion date
July 31, 2029
Enrollment
1,100 (estimated)
Sites
183

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer